Acrux delivers sweet medicine
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Shares in Acrux (ACR) jumped 1.4% to $3.55 this morning on news of a material increase in sales of its spray on testosterone treatment.
Pharmaceutical giant Eli Lily, which is the exclusive distributor of Acrux’s Axiron, reported sales of $US47 million in the June quarter, or a 27% increase from the previous quarter and a three-fold increase in nine months.
Total sales for Axiron reached $US124 million in the 2012-13 financial year and royalties paid to Acrux has jumped to $14 million from $6 million in the previous year.
Royalties are calculated as a percentage of sales and Acrux expects this percentage to increase in the current financial year as sales of Axiron hits certain milestones.
Speaking of milestones, Acrux will receive a $US25 million milestone payment from Eli Lily if worldwide net sales of Axiron exceed $US100 million in the 2013 calendar year. Acrux only needs $US16 million in additional sales from now to the end of the December to achieve this milestone.
Acrux is part of the Uncapped 100.
Call 1300 880 160
Start a chat
Schedule a call
